Clinical trial
Efficacy and Safety of NM-702 Tablets for the Treatment of Intermittent…
NCT00102050 · Nissan Chemical Industries, Industry · Completed
Key facts
| NCT number | NCT00102050 |
|---|---|
| Title | Efficacy and Safety of NM-702 Tablets for the Treatment of Intermittent Claudication |
| Official title | A Double-Blind, Randomized, Parallel Group, Placebo-Controlled Study to Evaluate the Safety and Efficacy of NM-702 in Subjects With Intermittent Claudication |
| Lead sponsor | Nissan Chemical Industries, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Intermittent Claudication, Peripheral Vascular Disease |
| Intervention type | Drug |
| Interventions | NM-702 (phosphodiesterase inhibitor) |
| Enrollment | 390 |
| Start date | Apr 1, 2003 |
| Completion | Apr 1, 2006 |
| First posted | Jan 20, 2005 |
| Last update posted | May 19, 2006 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: